NEO
NeoGenomicsBNasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-22
Current thesis
Rising test volumes, stable reimbursement, and successful roll-out of higher‑margin panels drive above‑consensus revenue growth and multiple expansion, supporting upside toward the bull target within 12 months.
Posture
Constructive
Lead driver
Momentum
What changed
Next scheduled catalyst: earnings 2026-07-28 · AMC.
What can break
Competition from liquid-biopsy and centralized labs
Momentum
99
Value
42
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $13.50 · Bull $16.50 · Bear $9.00
Earnings
2026-07-28 · AMC
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-07 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $16.22
Why
Momentum99 · Δ7d +0.6
Value42 · Δ7d +0.0
Sentiment51 · Δ7d -1.9
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
99
26% active weight
Current posture
7d trendFlat
Δ7d
+0.6
Δ21d
+1.4
Value
42
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Sentiment
51
34% active weight
Current posture
7d trendSoftening
Δ7d
-1.9
Δ21d
-0.9
Why this grade
Composite grade B. Momentum 98.6 / Value 41.6 / Sentiment 50.5
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$1.88B
Beta
1.57
Shares Out
130.21M
P/E (TTM) · Derived
-17.1
P/S (TTM)
2.20
P/FCF (TTM) · Derived
-375.32
Rev YoY
+11.1%
EPS YoY
-34.9%
Gross Margin
+40.9%
Op Margin
-17.0%
Net Debt
$249.84M
Current Ratio
4.42
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology